Healthy Volunteers Clinical Trial
Official title:
Reliability of Measuring Conditioned Pain Modulation With the Nociceptive Withdrawal Reflex
Conditioned pain modulation is the ability of the spine to describe changes in pain perception, if two different painful stimulations take place. The reliability of the conditioned pain modulation has not been studied, the instruments used to measure the conditioned pain modulation are sparse and have proven difficult to use in a well reproductible way. This study is using an existing pain test, relying on the reflex in a muscle after a painful electrical stimulation. We will test 34 healthy volunteers in order to test the reliability of the conditioned pain modulation with the nociceptive withdrawal reflex combined to a ice water test.
Background
Chronic pain is characterized by changes in the central processing of sensory inputs.
Quantitative sensory tests (QST) explore central excitability in humans and have the
potential to detect altered central pain processing in individual patients.
QST were developed to assess the responses to sensory stimuli for research purposes,
providing psychophysical and electrophysiological methods for the assessment of the
nociceptive system. Reliability is an essential condition for using QST in research and
clinical practice. It can be defined as the consistency of measurements across time,
patients or observers, and the extent to which it is error-free. Three categories have been
assessed for reliability in QST measures: intra-rater, inter-rater and test-retest
reliability. Reliability of QST measures in healthy volunteers are encouraging in regard to
good repeatability of QST measures over the time in the same subjects. Inter-rater
reliability, a prerequisite to compare different measures in between different studies, are
also highly encouraging.
Under normal conditions, pain after application of a test nociceptive stimulus is attenuated
by the application of an additional "conditioning" noxious stimulus to a remote body region,
reflecting diffuse endogenous inhibition. This is defined as conditioned pain modulation
(CPM), also known as the "pain inhibits pain" paradigm. CPM has been object of much work in
the last years. It goes back to the exploration of endogenous analgesia via descending
pain-modulatory systems, which started about three decades ago in animal models. Descending
inhibitory pathways are under cerebral control, mediating modulation of pain perception by
emotional, motivational and cognitive factors. Alterations of CPM are a known risk factor
concerning acute and chronic pain syndromes.
Very few reliability studies on CPM have been conducted to date. To our knowledge, only S.
Cathcart et al used occlusion cuff algometry and pressure pain detection to assess the
test-retest reliability in healthy volunteers. A study in chronic pain patients from our
group has shown great variability in CPM. It is unclear whether this phenomenon is related
to high interindividual variability of the CPM measure itself, or to poor reliability. In an
analysis of own data extracted from a pharmacological study, CPM measured at three different
sessions in patients with low back pain displayed very poor reliability.
The nociceptive withdrawal reflex is an electrophysiological measure. Compared to
psychophysical measures which rely on the subject's pain perception, the reflex could be a
more reproducible and stable measure over time.
Objective
The primary aim of the present study is to assess the reliability of CPM using the
nociceptive withdrawal reflex as test stimulus and the ice water test as conditioning
stimulus in 34 consecutive patients, with a 7 days interval between two sessions.
Secondary aim is to compare the reliability of CPM with the nociceptive withdrawal reflex to
the reliability of CPM assessed with subjective pain assessments, i.e. pain threshold and
pain intensity after electrical stimulation.
Methods
Repeated assessments of CPM using the nociceptive withdrawal reflex threshold, electrical
pain detection threshold and suprathreshold electrical stimulation of the skin, with
ice-water as conditioning stimuli in all three models. There will be a 7 days interval
between two measurements.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
| Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
| Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
| Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
| Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
| Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
| Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
| Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
| Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
| Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
| Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
| Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
| Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
| Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
| Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
| Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
| Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
| Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |